Targeted therapy of multiple myeloma
- سال انتشار: 1403
- محل انتشار: دومین کنگره بین المللی کنسرژنومیکس
- کد COI اختصاصی: ICGCS02_098
- زبان مقاله: انگلیسی
- تعداد مشاهده: 163
نویسندگان
Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
چکیده
Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of malignant plasma cells. Therapeutic options for MM include non-targeted drugs like alkylating agents, corticosteroids, immunomodulatory drugs, proteasome inhibitors, and histone deacetylase inhibitors. Non-targeted drugs, while effective, can also harm normal healthy cells, leading to adverse effects such as gastrointestinal problems (nausea, vomiting, diarrhea, and constipation) myelosuppression (reduction in white blood cells and platelets), alopecia, anemia, liver and kidney impairment, and an increased risk of infections. The pathogenesis of MM involves the interaction between MM cells and the bone marrow microenvironment through soluble cytokines and cell adhesion molecules, which activate various signaling pathways such as PI۳K/AKT/ mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways. Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma cells, making them attractive targets for therapeutic intervention. Currently, approved drugs targeting these signaling pathways in MM are limited, with many inhibitors and inducers still in preclinical or clinical research stages. For example, Afuresertib, AZD۶۲۴۴, Atiprimod, BHQ۸۸۰/DKK۱, and Carfilzomib are the inhibitors of Akt, MEK, STAT۳, Wnt, and NF-kB, respectively. Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an immune response. Drugs of targeted immunotherapy such as monoclonal antibodies, chimeric antigen receptor T cells, bispecific T-cell engagers, and bispecific antibodies are being used in MM treatment. These drugs target various antigens on MM cells and induce death in these cells through various mechanisms. Despite significant advancements in MM treatment, the disease remains incurable, emphasizing the need for the development of novel or combined targeted therapies based on emerging theoretical knowledge, technologies, and platforms. This review highlights the key role of signaling pathways in the malignant progression and treatment of MM, exploring advances in targeted therapy and potential treatments to offer further insights for improving MM management and outcomes.کلیدواژه ها
Multiple myeloma, Signaling pathways, Targeted therapy, Immunotherapiesمقالات مرتبط جدید
- هوش مصنوعی در تشخیص زودهنگام سرطان روده بزرگ: یک مطالعه مروری
- ویتامین ب ۱۲ و نقش آن در برابر سرطان مرور جامع
- نقش هوش مصنوعی در آینده درمان سرطان
- نقش نگرانی از تصویر بدنی و ترس از ارزیابی منفی در نشانه های بدریخت انگاری بدن در زنان مبتلا به سرطان پستان
- بررسی پخش ذرات معلق سرب روی بخش جنوبی محوطه دانشگاه زنجان با هدف پیشگیری از سرطان ریه غیر مرتبط با سیگار
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.